TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31124367
Drug: Liberal perioperative
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal perioperative oxygen therapy (≥80% oxygen)
Study: 31124367
Drug: Routine titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine titration of inspired oxygen
Study: 31124367
Drug: Minimising oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimising oxygen administration
Study: 31124367
Drug: Maximising oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximising oxygen administration
Study: 25596881
Drug: Levodopa treatment
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa treatment initiated after baseline assessment
Study: 23980876
Drug: Intratumoral plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral plasmid AMEP electrotransfer (1 and 2 mg DNA)
Study: 19411053
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 50) watched 4 weekly episodes of the cooking show, Good Grubbin'
Study: 19411053
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 51) watched 4 weekly episodes on sleep disorders
Study: 17724537
Drug: Therapeutic guidelines
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic guidelines for the treatment of nosocomial pneumonia (group with intervention)
Study: 12040756
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (no HBO)
Study: 9808859
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (GTN) 800 microg
Study: 2539204
Drug: Imipramine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (2.5 mg/kg/day)
Study: 2539204
Drug: Tyrosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (100 mg/kg/day)
Study: 6185089
Drug: Topical arabinosyladenine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical arabinosyladenine monophosphate (ara-AMP)
Study: 21203735
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent sodium ascorbate gel combined with a surfactant
Study: 21203735
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent carbamide peroxide without an antioxidant agent
Study: 28240687
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold < 9 g/dL)
Study: 28240687
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin threshold < 7 g/dL)
Study: 23880333
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) group, 8 weeks duration, 1 session per week, 100 minutes per session
Study: 17499084
Drug: Self-administered ERP
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered ERP
Study: 17499084
Drug: Therapist-administered ERP
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-administered ERP
Study: 15240647
Drug: Isoflavonoids (114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavonoids (114 mg/d)
Study: 11802014
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice a day for 2 months
Study: 9587133
Drug: Malignant lymphoma/multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malignant lymphoma/multiple myeloma (ML/MM)
Study: 3130925
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 60 mg APD intravenously
Study: 3130925
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 30 mg APD (two days) or 15 mg (four days)
Study: 31290697
Drug: Juice-based targeted
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice-based targeted medical nutrition (TMN) supplement (∼200 kcal; 10 g whey protein; ≥2.0 g eicosapentaenoic acid/docosahexaenoic acid in fish oil; and 10 μg 25-hydroxy-vitamin D3)
Study: 19181969
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with orthosis (22 patients)
Study: 11804384
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment approaches (surgery, radiation, chemotherapy, BSC)
Study: 9440748
Drug: Single-dose (pulse-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (pulse-intensive [PI]) treatment with dactinomycin for low-risk patients
Study: 9440748
Drug: Divided-dose (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided-dose (standard [STD]) treatment with dactinomycin for low-risk patients
Study: 9440748
Drug: Single-dose (pulse-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (pulse-intensive [PI]) treatment with doxorubicin for high-risk patients
Study: 9440748
Drug: Divided-dose (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided-dose (standard [STD]) treatment with doxorubicin for high-risk patients
Study: 2684073
Drug: Betaxolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (20 mg once daily)
Study: 2684073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Betaxolol and Chlorthalidone
Study: 31000379
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and phenylephrine nasal spray (10 mg lidocaine and 1 mg phenylephrine for children weighing 6–12 kg; 20 mg lidocaine and 2 mg phenylephrine for children weighing >12 kg)
Study: 31000379
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride placebo nasal spray
Study: 31000379
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and phenylephrine nasal spray
Study: 25540891
Drug: EBO vaccine
Normalized name: ERVEBO Vaccine Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBO vaccine
Study: 25540891
Drug: MAR vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAR vaccine
Study: 20140352
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine during pregnancy (Group 1)
Study: 20140352
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine after pregnancy (Group 2)
Study: 20140352
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (Group 3)
Study: 9604230
Drug: Weight-adjusted LT4-dose
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-adjusted LT4-dose in combination with 150 micrograms iodide (group A)
Study: 9604230
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 100 micrograms LT4 plus 100 micrograms iodide (group B)
Study: 1655350
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 150 mg/die i.v. for 10 days
Study: 1655350
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1,000 mg/die i.v. for 10 days
Study: 31529492
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (physician's choice with either methotrexate or bexarotene)
Study: 27955919
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa (2.0 mg/kg) administered weekly or every other week for 120 weeks
Study: 21309194
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose 90 mg/dL or greater
Study: 21309194
Drug: 1 hour
Normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour glucose 165 mg/dL or greater
Study: 21309194
Drug: 1 hour
Normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour glucose 150 mg/dL or greater
Study: 15268892
Drug: Risedronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (30 mg daily for 10 doses during the first 2 weeks, then once a week for 12 weeks)
Study: 11296884
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose administration of 60 mg dihydrocodeine
Study: 11296884
Drug: Chronic high-dosage
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic high-dosage administration of dihydrocodeine
Study: 8037259
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg p.o.)
Study: 4309863
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral corticosteroids (0.3‐0.4 mg. of betamethasone disodium phosphate daily)
Study: 4309863
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral hydrocortisone hemisuccinate (10 mg. daily for up to three years)
Study: 4309863
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral betamethasone 17‐valerate (0.4 mg. per day)
Study: 4309863
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral hydrocortisone hemisuccinate and betamethasone 17‐valerate
Study: 4309863
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral betamethasone disodium phosphate
Study: 28980935
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (5x10^9 cfu/capsule) for 8 weeks
Study: 23982366
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d of sofosbuvir and weight‐based ribavirin for 24 weeks
Study: 23982366
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of sofosbuvir with weight‐based ribavirin for 24 weeks
Study: 23982366
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of sofosbuvir with low‐dose 600 mg/d of ribavirin for 24 weeks
Study: 17392695
Drug: Isoflavone intake
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone intake <90 mg/day
Study: 10895746
Drug: Triamcinolone 20
Normalized name: triamcinolone 20 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 20 mg
Study: 10895746
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid (0 mg)
Study: 3310826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.030 mg ethinylestradiol and 0.150 mg levonorgestrel
Study: 3310826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.030 mg ethinylestradiol and 0.150 mg desogestrel
Study: 3310826
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.030 mg ethinylestradiol and 0.150 mg levonorgestrel)
Study: 3310826
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.030 mg ethinylestradiol and 0.150 mg desogestrel)
Study: 31948767
Drug: Ivermectin MDA
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin MDA with three consecutive daily doses of 300 μg/kg (3×300 μg/kg)
Study: 27921413
Drug: Low-dose phototherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phototherapy (mixture of UVA, UVB, and visible light)
Study: 24693926
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment at the hospital plus a weekly session with a peer of their choice (Experimental group)
Study: 24693926
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment at the hospital plus a weekly interactive and physical activity session (Comparison group)
Study: 23799702
Drug: Prescription plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription plus referral intervention (n = 12)
Study: 23799702
Drug: Prescription only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription only intervention (n = 12)
Study: 18480190
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation (physical training twice weekly + cognitive-behavioral training once weekly)
Study: 18480190
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (twice weekly)
Study: 15321086
Drug: i.v. glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. glycopyrrolate 4.0 microg/kg (group G)
Study: 9014624
Drug: Lignocaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1% (5 ml) instilled hourly for 12 h
Study: 9014624
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (5 ml) instilled hourly for 12 h
Study: 3883172
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (2.5 to 5 mg every 12 hours for three doses weekly)
Study: 27624603
Drug: Conventional loop
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loop diuretics (Group C)
Study: 25373935
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing high sn-2 palmitate plus 3 g/L oligofructose (sn-2+OF; n=55)
Study: 22932428
Drug: i.v. amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. amphetamine dose of 0.3 mg/kg bodyweight
Study: 18444166
Drug: Topical perillyl
Normalized name: perilla frutescens top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical perillyl alcohol (POH) cream (0.76% wt/wt) applied twice daily for 30 days
Study: 18444166
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 30 days
Study: 359140
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment (low-level physical activity sessions, 14 of 18 sessions over 6 weeks)
Study: 28341259
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (1000 IU daily) and isokinetic training (3 times per week at 150°/s)
Study: 28341259
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (1000 IU daily) and isokinetic training
Study: 19457978
Drug: Physiotherapy staff
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy staff recording of treatment time
Study: 19457978
Drug: Video recording
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video recording of treatment time
Study: 16710580
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment 4 times daily
Study: 16710580
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% ointment 4 times daily
Study: 15471389
Drug: Aspirin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250 mg on admission, then 125 mg/day)
Study: 15471389
Drug: Cardiomagnil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiomagnil (150 mg on admission, then 75 mg/day)
Study: 15471389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel (75 mg/day) and cardiomagnil (75 mg/day)
Study: 11204665
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with novel agents (e.g., thymidylate synthase inhibitors, epidermal growth factor‐receptor antagonists, microtubule interactive agents)
Study: 9278830
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg intravenously (IV)
Study: 9278830
Drug: droperidol 25
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: droperidol 25 mcg/kg i.v.
Study: 8318783
Drug: Intraperitoneal injection
Normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of DDP at doses of 110 mg/m2
Study: 8318783
Drug: Intraperitoneal injection
Normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of DDP at doses of 70 mg/m2
Study: 8318783
Drug: Intraperitoneal injection
Normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of DDP with sodium thiosulfate (STS) rescue
Study: 3519886
Drug: PC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days)
Study: 3519886
Drug: PAC (PC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (PC + doxorubicin 45 mg/m2)
Study: 29631435
Drug: Dexamethasone 0.7
Normalized name: dexamethasone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.7 mg at day 1 and month 5, with optional retreatment at month 10 or 11.
Study: 29631435
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg at day 1 and monthly through month 5, with as-needed injections at month 6-11.
Study: 27406647
Drug: Coupled plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coupled plasma filtration adsorption (CPFA) with treated plasma ≥0.20 L/kg/day in the first 3 days after randomisation.
Study: 18799820
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/d, n = 30)
Study: 18799820
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/d, n = 30)
Study: 10480471
Drug: 81 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg/day ASA
Study: 10480471
Drug: 325 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg/day ASA
Study: 8531541
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with Goretex bedcovers, benzyltannate spray, and a high‐filtration vacuum cleaner.
Study: 8531541
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with cotton covers, water spray, and a conventional domestic vacuum cleaner.
Study: 1830393
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride treatment
Study: 30700619
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine at 8 mL/h
Study: 30700619
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of 0.2% ropivacaine at 8 mL/h
Study: 30700619
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine
Study: 30700619
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of 0.2% ropivacaine
Study: 15682244
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cotrimoxazole (4 mg trimethoprim plus 20 mg sulfamethoxazole/kg)
Study: 15682244
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose cotrimoxazole (8 mg trimethoprim plus 40 mg sulfamethoxazole/kg)
Study: 12692782
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation (IAD) therapy
Study: 10594485
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg TA orally
Study: 10594485
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg glibenclamide orally
Study: 10594485
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg TA+3.5 mg glibenclamide
Study: 10594485
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg TA+50 mg acarbose
Study: 1812314
Drug: tannalbuminate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: tannalbuminate (500 mg) and ethacridin‐lactate (50 mg), 1 tbl. b.i.d.